- Trial Phase
- Phase 2
- Time to Market
- Estimated 3-5 years. The drug is in Phase 2; a Phase 3 registrational trial has not yet been initiated. Even with a potential accelerated path, FDA submission is likely several years away.
- Why 4/10
- No hard dated binary catalyst (PDUFA, pivotal readout, or Advisory Committee) is scheduled within the next ~12 months. The Phase 2 ARC-20 data was just presented on October 20, 2026. The next catalyst would be additional data at a medical conference or initiation of a Phase 3 trial, neither of which has a confirmed date. Casdatifan is the lead value driver for RCUS, but without a near-term binary event, the impact score defaults to 4.
Watch for the next ARC-20 data update at a medical conference (likely 2027) and any announcement of a Phase 3 registrational trial start. The $250M capital raise at a discount signals near-term cash needs despite positive data; monitor for further dilution risk. The stock is technically oversold (RSI 27.5) with strong analyst support, but no hard binary catalyst is scheduled within the next 12 months.
Price Chart
Executive Summary
Casdatifan is Arcus Biosciences' lead pipeline asset — a HIF-2α inhibitor in Phase 2 development for clear cell renal cell carcinoma (ccRCC). Positive Phase 2 ARC-20 data presented October 20, 2026 showed a 50% confirmed objective response rate (cORR) in first-line combination and 36% cORR in late-line monotherapy. The company raised $250M in a dilutive public offering days later to accelerate the program. While early efficacy data is encouraging, casdatifan faces entrenched competition from Merck's already-approved HIF-2α inhibitor Welireg (belzutifan), and the stock has sold off sharply from its 52-week high of $31.74 to $18.54, with a bearish technical setup. Analyst consensus is Strong Buy with a mean price target of $41 (134.6% implied upside), but the company burns ~$182M/quarter and has no near-term binary catalyst scheduled.
How It Works
Casdatifan is a HIF-2α inhibitor — it blocks a protein called hypoxia-inducible factor 2 alpha that cancer cells (especially in kidney cancer) use to survive and grow when oxygen levels are low. By turning off this protein, the drug aims to starve tumors of their growth signals. It is taken orally as a pill.
Trial Status
The ARC-20 Phase 2 study in clear cell renal cell carcinoma (ccRCC) reported positive topline data on October 20, 2026. In the first-line combination arm, casdatifan plus an anti-PD-1 inhibitor (zimberelimab) showed a 50% confirmed objective response rate (cORR). In the late-line monotherapy arm, casdatifan alone showed a 36% cORR. The company is using the $250M capital raise to expand and accelerate the casdatifan clinical program, likely toward a registrational Phase 3 trial.
The Two-Sided Case
Upcoming Catalysts
- Next ARC-20 data update at a medical conference (likely ESMO or ASCO GU in 2027)
- Initiation of a Phase 3 registrational trial for casdatifan in ccRCC
- Potential partnership or licensing deal for casdatifan (Gilead is a related-party partner on other Arcus assets)
- Q3 2026 earnings report (expected late October/November 2026)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Arcus Biosciences, Inc. 8-K RCUS ·Originating report